Valproate Therapy

Indications and Efficacy

Valproate is particularly effective in refractory status epilepticus, with studies showing 79% seizure control when used as a second-line agent versus 25% with phenytoin, as reported by the American College of Emergency Physicians 1, 2
The American Academy of Neurology suggests that valproate may be especially useful in patients with prolonged or atypical migraine aura 3
The American Headache Society indicates that valproate has established efficacy for migraine prophylaxis with good evidence from multiple clinical trials 4, 3
The American Academy of Neurology recommends valproate for chronic daily headache, based on small trials supporting its efficacy 5, 3
The American College of Obstetricians and Gynecologists advises that valproate is not recommended for migraine prevention in women of childbearing potential due to teratogenic risk 6

For status epilepticus, the American College of Emergency Physicians recommends valproate dosing at 30 mg/kg IV at 6 mg/kg/hour, followed by infusion at 1-2 mg/kg/hour 1, 2
The American Academy of Neurology suggests that typical dosing for migraine prevention is similar to seizure management, with therapeutic blood levels typically maintained between 50-100 μg/mL 5, 3

The American Academy of Child and Adolescent Psychiatry recommends monitoring for weight gain, with valproate associated with weight gain in some patients 5, 7
The American College of Neurology advises that valproate is associated with a risk of teratogenicity, with a 1-3% risk of neural tube defects, and is absolutely contraindicated in women of childbearing potential 6
The American Academy of Child and Adolescent Psychiatry suggests that regular monitoring of hepatic and hematological indices is necessary during valproate therapy 7
The American Academy of Child and Adolescent Psychiatry recommends body mass index monitoring due to potential weight gain 7

The American College of Neurology advises that valproate is contraindicated in patients with thrombocytopenia 6